Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Elon Musk
Apple
OnePlus
NOTHING
Latest Laptops
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Technology News / Russia's Sputnik V at least 91% effective, early data suggests
Technology

Russia's Sputnik V at least 91% effective, early data suggests

Russia's Sputnik V at least 91% effective, early data suggests
Written by Siddhant Pandey
Nov 24, 2020, 07:51 pm 3 min read
Russia's Sputnik V at least 91% effective, early data suggests

The Russian vaccine for COVID-19, called Sputnik V, has been found at least 91% effective in the second interim analysis. According to a press release, the vaccine was found to be 91.4% effective seven days after the second dose was administered, and 95% effective two weeks later. Notably, human trials for the vaccine are set to begin in India this week.

Data
8 out of 39 participants who contracted COVID-19 received vaccine

An analysis conducted seven days after the second dose (28 days after the first dose) found the vaccine to be 91.4% effective. Out of the 18,794 trial participants, 14,095 had received the vaccine dose while 4,699 were in the placebo group (in a 3:1 ratio). Of the 39 confirmed COVID-19 infections among participants, only eight were those who had received the vaccine.

Information
21 days after second dose, over 95% efficacy observed

Preliminary data from volunteers obtained 21 days after the second dose—42 days after the first dose—indicated efficacy of above 95%, the press release stated. Notably, as of Tuesday, over 22,000 participants had received the first dose, while over 19,000 had received first and second doses.

Analysis
Final data will be available after Phase III trials

As per protocol, Sputnik V's interim efficiency is to be calculated when COVID-19 infections among trial participants reach 20, 39, and 78. The latest data is from the second interim analysis when 39 cases have been confirmed. The next interim data will be conducted when there are 78 COVID-19 cases among participants. Final data will be available after Phase III trials conclude.

Trials
No unexpected adverse events observed during trials

Currently, there are 40,000 participants in Phase III double-blind, randomized, placebo-controlled clinical post-registration study of the Sputnik V vaccine in Russia. There were no unexpected adverse events during the trials, the release said. However, participants continue to be monitored currently. Gamaleya Center will provide access to the full clinical trial report after the Phase III trials are complete.

Quote
'We believe final results will exceed expectations'

Mikhail Murashko, Minister of Health of the Russian Federation, said, "The data demonstrating high efficacy of the Sputnik V vaccine gives us hope that we will soon obtain the most important tool in the fight against the pandemic of the novel coronavirus infection." Meanwhile, Alexander Gintsburg, Gamaleya Center Director, said they had "every reason to believe that the (final) results will exceed our expectations."

Quote
'Our vaccine's price two times lower than competitors'

RDIF CEO Kirill Dmitriev said, "Gamaleya Center has developed one of the most efficient vaccines against coronavirus in the world with an efficacy rate of more than 90% and a price that is two times lower than that of other vaccines with similar efficacy rate." Dmitriev said the "use of two different human adenoviral vectors...allows for a stronger and longer-term immune response."

Information
How have the other vaccine candidates fared?

Among other leading vaccine candidates, Moderna has said that its product has 94.5% efficacy. Pfizer and BioNTech's vaccine candidate has been found 95% effective, while Oxford University and AstraZeneca's candidate—dubbed 'Covishield' in India—has an average efficacy of 70%, which can be increased to 90% through dosing.

India
India to receive 100 million doses of Sputnik V

Earlier it had been reported that Phase II-III combined trials for Sputnik V will start in India this week. The Hyderabad-based Dr. Reddy's Laboratories has struck a deal to conduct vaccine trials and distribution of the vaccine in India. India is expected to receive 100 million doses of the potential vaccine, developed jointly by the Russian Direct Investment Fund (RDIF) and the Gamaleya Institute.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
Pfizer
Oxford University
BioNTech
AstraZeneca
Moderna Inc
Latest
Earthshine Moon July 2022: When and how to watch it?
Earthshine Moon July 2022: When and how to watch it? Technology
'Meri Patni Ka Remake': Makers rope in Arjun, Bhumi, Rakul
'Meri Patni Ka Remake': Makers rope in Arjun, Bhumi, Rakul Entertainment
Assamese actor Kishor Das succumbs to cancer, dies at 30
Assamese actor Kishor Das succumbs to cancer, dies at 30 Entertainment
Who is Rahul Narwekar, Maharashtra Assembly's new Speaker?
Who is Rahul Narwekar, Maharashtra Assembly's new Speaker? India
Decoding the run of Spain's Paula Badosa in 2022
Decoding the run of Spain's Paula Badosa in 2022 Sports
Pfizer
New Omicron sub-variants can trigger new COVID-19 wave: Study
New Omicron sub-variants can trigger new COVID-19 wave: Study World
Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine
Pfizer, BioNTech begin clinical trial for Omicron-specific vaccine World
'Cautious optimism' after initial Omicron studies; here's what we know
'Cautious optimism' after initial Omicron studies; here's what we know Technology
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective Technology
COVID-19: India reports 10K+ infections; 301 more deaths
COVID-19: India reports 10K+ infections; 301 more deaths India
More News
Oxford University
COVID-19 vaccine maker Professor Sarah Gilbert honored with Barbie doll
COVID-19 vaccine maker Professor Sarah Gilbert honored with Barbie doll World
AstraZeneca vaccine's single dose reduces death risk by 80%: Data
AstraZeneca vaccine's single dose reduces death risk by 80%: Data World
#OxfordUniversity racism row: India to raise the issue when required
#OxfordUniversity racism row: India to raise the issue when required India
Five killed in Serum Institute fire; Maharashtra government orders probe
Five killed in Serum Institute fire; Maharashtra government orders probe India
Maldives to become first foreign country to receive Covishield doses
Maldives to become first foreign country to receive Covishield doses World
More News
BioNTech
Pfizer-BioNTech vaccine 'safe' for kids aged 5-11; generates 'robust immunity'
Pfizer-BioNTech vaccine 'safe' for kids aged 5-11; generates 'robust immunity' World
England school children aged 12-15yrs to be offered COVID-19 vaccine
England school children aged 12-15yrs to be offered COVID-19 vaccine World
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA World
Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week
Pfizer-BioNTech COVID-19 vaccine to get US-FDA's full approval next week World
Pfizer-BioNTech's coronavirus vaccine being tested on children under 12
Pfizer-BioNTech's coronavirus vaccine being tested on children under 12 World
More News
AstraZeneca
AstraZeneca's antibody cocktail Evusheld effective against Omicron, finds study
AstraZeneca's antibody cocktail Evusheld effective against Omicron, finds study World
Kim orders tougher virus steps after North Korea shuns vaccines
Kim orders tougher virus steps after North Korea shuns vaccines World
Pfizer, AstraZeneca vaccines less effective against Delta variant: Oxford study
Pfizer, AstraZeneca vaccines less effective against Delta variant: Oxford study World
India mulls mixing Covishield, Sputnik doses; no recommendation yet
India mulls mixing Covishield, Sputnik doses; no recommendation yet India
France allows visitors vaccinated with Indian-made AstraZeneca vaccine
France allows visitors vaccinated with Indian-made AstraZeneca vaccine World
More News
Moderna Inc
Moderna COVID-19 vaccine produces lasting immune response: Study
Moderna COVID-19 vaccine produces lasting immune response: Study Technology
Japan suspends 1.63mn Moderna vaccine doses after contamination found
Japan suspends 1.63mn Moderna vaccine doses after contamination found World
No sign of Pfizer, Moderna vaccines in breast milk: Study
No sign of Pfizer, Moderna vaccines in breast milk: Study Technology
India offered 7.5mn doses of Moderna vaccine under COVAX program
India offered 7.5mn doses of Moderna vaccine under COVAX program India
Moderna vaccine arriving in India in 2-3 days: Report
Moderna vaccine arriving in India in 2-3 days: Report India
More News
Next News Article
Next News Article

Love Technology news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022